RESULTS
Between January 6, 2021, and July 9, 2021, 63 patients were assessed for eligibility. Of the total patients screened, 61 (96.8%) met the eligibility criteria and were enrolled and randomly assigned to receive either ixekizumab (n = 16 [25.8%]), low-dose IL-2 (n = 15 [24.6%]), colchicine (n = 14 [22.6%]), or SOC alone (n = 16 [25.8%]). Participants received the allocated intervention and were included in the “per-protocol” analysis. The flow diagram of the study is shown in 
